Navigation Links
Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories Agency

PORTON DOWN, England, June 30 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today successful independent testing for bovine viral diarrhoea (BVD) by the Veterinary Laboratories Agency to evaluate the performance of the Enigma FL (Field Laboratory).

BVD is considered to be one of the main threats to cattle (1), affecting the majority of herds in the UK. It is closely related to classical swine fever virus, a serious disease of pigs, and to border disease virus, which infects sheep.

The Enigma FL instrument was used to analyse more than 100 blood samples that had already been screened by antigen ELISA and a laboratory-based RT-PCR for the presence of the BVD virus. Approximately half of the samples were proved BVDV positive by the laboratory-based PCR. With the level of concordance between the two tests being above 97%, this confirmed the Enigma FL system can produce laboratory-standard results with a high degree of confidence.

The Enigma FL has been designed for easy operation. Tests are provided in a single-use cartridge that can be stored at room temperature. The Enigma FL provides a PCR result in less than one hour, a timescale needed to allow field-based & pen-side diagnosis. On-site testing removes delays from transport of samples to the laboratory, which can often take days. The system requires minimal training and its utility for "pen-side" testing for BVD has already been demonstrated.(2)

John McKinley, Chairman and CEO of Enigma, stated: "The Enigma Diagnostics tests could be deployed for the related viral diseases, such as classical swine fever, with minor modifications. The system itself is broadly applicable to many other veterinary pathogens, such as TB in cattle, bacterial infections and other viral infections, such as foot and mouth disease and avian influenza. Allowing vets to use advanced molecular diagnosis in the field will enhance their efficiency in managing endemic and exotic disease outbreaks identifying diseased animals and as importantly, non-infected ones and improve their surveillance capability."




    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    +44 1980 590131

    US Contact:
    Richard Lewis Communications, Inc.
    Gregory Tiberend - Media
    Cecelia Heer - Investors

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive licence from the Defence Science and Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit

SOURCE Enigma Diagnostics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
2. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
3. Enigma Signs Real-Time PCR Licences With Applera
4. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
5. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
6. Enigma Diagnostics Announces the Opening of a United States Office
7. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
8. Strategic Diagnostics Updates Roth Conference Presentation Time
9. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
10. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
11. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
Breaking Biology Technology:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):